Target hemoglobin level for EPO therapy in CKD.
Parfrey
Patrick S
PS
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002908:Chronic Disease; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006040:Goals; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000150:complications* / Q000401:mortality / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000401:mortality / Q000628:therapy; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects; D019851:Thrombophilia / Q000139:chemically induced
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin